Who owns Upstream Bio, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of UPB from SEC Form 13F filings across 135 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 135 institutions disclosed 48.1M shares of Upstream Bio, Inc. worth $253.3M — about 87.8% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
135
13F holders
$253.3M
value, 2026 filers
87.8%
of shares outstanding (48.1M sh)
18
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of UPB's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 8.2M | $43.1M | 0.0% | 14.9% | +0.2% |
| 2 | ORBIMED ADVISORS LLC | 5.7M | $30.0M | 0.5% | 10.4% | 0.0% |
| 3 | BlackRock, Inc. | 3.7M | $19.4M | 0.0% | 6.7% | -1.8% |
| 4 | Decheng Capital LLC | 2.7M | $14.4M | 2.1% | 5% | 0.0% |
| 5 | ENAVATE SCIENCES GP, LLC | 2.5M | $13.0M | 4.6% | 4.5% | 0.0% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | $10.3M | 0.0% | 3.6% | +4.4% |
| 7 | JPMORGAN CHASE & CO | 1.5M | $7.6M | 0.0% | 2.7% | +44.1% |
| 8 | D. E. Shaw & Co., Inc. | 1.4M | $7.4M | 0.0% | 2.6% | +35.0% |
| 9 | MILLENNIUM MANAGEMENT LLC | 1.2M | $6.2M | 0.0% | 2.1% | +2.1% |
| 10 | GOLDMAN SACHS GROUP INC | 1.1M | $5.9M | 0.0% | 2.1% | +356.4% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 972,580 | $5.1M | 0.0% | 1.8% | +4.4% |
| 12 | Qube Research & Technologies Ltd | 926,237 | $4.9M | 0.0% | 1.7% | -5.3% |
| 13 | SEB Asset Management AB | 878,473 | $4.6M | 0.0% | 1.6% | 0.0% |
| 14 | Woodline Partners LP | 831,481 | $4.4M | 0.0% | 1.5% | 0.0% |
| 15 | Trexquant Investment LP | 766,231 | $4.0M | 0.0% | 1.4% | +64.3% |
| 16 | VANGUARD PORTFOLIO MANAGEMENT LLC | 755,981 | $4.0M | 0.0% | 1.4% | +6.1% |
| 17 | STATE STREET CORP | 736,488 | $3.9M | 0.0% | 1.3% | -3.9% |
| 18 | BNP PARIBAS FINANCIAL MARKETS | 730,278 | $3.8M | 0.0% | 1.3% | +42.8% |
| 19 | Y-Intercept (Hong Kong) Ltd | 642,574 | $3.4M | 0.1% | 1.2% | -7.4% |
| 20 | MORGAN STANLEY | 635,905 | $3.4M | 0.0% | 1.2% | +21.2% |
| 21 | Parkman Healthcare Partners LLC | 618,056 | $3.3M | 0.3% | 1.1% | -33.9% |
| 22 | Voleon Capital Management LP | 477,306 | $2.5M | 0.0% | 0.9% | +67.3% |
| 23 | TWO SIGMA INVESTMENTS, LP | 428,190 | $2.3M | 0.0% | 0.8% | +911.7% |
| 24 | AQR CAPITAL MANAGEMENT LLC | 415,734 | $2.2M | 0.0% | 0.8% | -23.7% |
| 25 | DIMENSIONAL FUND ADVISORS LP | 374,836 | $2.0M | 0.0% | 0.7% | -1.8% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.